DonaldWilliamKufeMD

Oncology • Boston, MA

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Kufe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kufe's full profile

Already have an account?

Office
450 Brookline Ave
D830
Boston, MA 02215
Phone+1 617-632-3141

Fax+1 617-632-2934

Education & Training

George Washington UniversityResidency, Internal Medicine, 1975 - 1977
Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1970 - 1971
University of Rochester School of Medicine and DentistryClass of 1970

Certifications & Licensure

MA State Medical License 1977 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1982

Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1999 Mar 03
Completed
Phase 1
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 1996 Dec 01
Completed
Phase 1

Publications & Presentations

PubMed

2 citations
Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".
Naoki Haratake, Donald Kufe
Journal of Thoracic Oncology. 2024-12-01
MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer.
Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya
Biomedicines. 2024-07-08
2 citations
MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.
Atrayee Bhattacharya, Keyi Wang, Johany Penailillo, Chi Ngai Chan, Atsushi Fushimi
Oncogene. 2024-07-01

Journal Articles

Targeting the Human MUC1-C Oncoprotein with an Antibody-Drug Conjugate
Qing Zhao, Donald Kufe, The Journal of Clinical Investigation

Abstracts/Posters

Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma
Donald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion Vaccine
Donald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular Therapy
Donald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model
Donald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematologi...
Donald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/2019
Join now to see all

Lectures

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31st, 2023

Grant Support

Functional Role Of The MUC1-C Oncoprotein In Non-Small Cell Lung CancerNational Cancer Institute2012
Adoptive Immunotherapy For Multiple Myeloma Using Educated T CellsNational Cancer Institute2010–2012
Early Clinical Trials Of New Anti-Cancer Agents With Phase I EmphasisNational Cancer Institute2008–2012
P5 - Adoptive Immunotherapy For Renal Carcinoma Usng Dendritic Cell/Tumor FusionsNational Cancer Institute2010–2011
Oncogenic Signaling By DF3/MUC1 In Human Breast CancerNational Cancer Institute2002–2011
Differentiating Agents In Hematologic MalignanciesNational Cancer Institute1986–2011
Adoptive Immunotherapy For Renal Carcinoma Using Dendritic Cell/Tumor FusionsNational Cancer Institute2009
Novel Immunotherapeutic Approaches For Ovarian CancerNational Cancer Institute2004–2008
Regulation Of Oxidative Stress Response By C-ABL And ARGNational Cancer Institute2003–2007
Phase I Trials Of New Anti-Cancer AgentsNational Cancer Institute2003–2007
Molecular Mechanisms Of ARA-C Therapy In ManNational Cancer Institute1987–2005
Development Of Myeloma VaccinesNational Cancer Institute1998–2002
Molecular Regulation Of Signaling By Ionizing RadiationNational Cancer Institute1996–2002
Phase I Trials Of New Anticancer AgentsNational Cancer Institute1994–2002
Oncogenic Signaling By The MUC1 Breast Carcinoma AntigenNational Cancer Institute2000–2001
Phosphorylation Of RAD51National Center For Research Resources1998–2001
Core--Cancer PharmacologyNational Cancer Institute2000
DF3/MUC1 Vaccine And Stamp Therapy For Breast CancerNational Cancer Institute1997–1998
Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
Molecular Regulation Of C-Jun By Ionizing RadiationNational Cancer Institute1992–1994
Clonality In Acute Myeloid Leukemia And MyelodysplasiaNational Cancer Institute1991–1992
Immunodiagnostic Approaches To Human Breast CancerNational Cancer Institute1985–1990
Molecular Mechanisms Of ARA C Therapy In ManNational Cancer Institute1985–1986
Molecular Mechanisms Of 5-Fluorouracil ChemotherapyNational Cancer Institute1985–1986